Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical characteristics of the study population

From: The effect of concomitant fibromyalgia in HIV infected patients receiving antiretroviral therapy: a prospective cross-sectional study

  Total number of patients
n = 225 (%)
With FMS
n = 45 (%)
Without FMS
n = 180 (%)
p* values
Gender
 Female 33 (14.7%) 9 (4%) 24 (10.7%) 0.258
 Male 192 (85.3%) 36 (16%) 156 (69.3%)  
Median age (year) 40.52 ± 12.98 41.93 ± 11.24 40.17 ± 13.38 0.415
Marital status
 Married 84 (37.3%) 15 (6.7%) 69 (30.7%) 0.535
 Single 141 (62.7%) 30 (13.3%) 111 (49.3%)  
Working status
 Working 135 (60%) 24 (10.7%) 111 (49.3%) 0.307
 Not working 90 (40%) 21 (9.3%) 69 (30.7%)  
Duration of HIV infection (year) 4.74 ± 4.42 6.36 ± 5.83 4.29 ± 3.84 0.007
Comorbidity
 Yes 36 (16%) 12 (5.3%) 24 (10.7%) 0.029
 No 189 (84%) 33 (14.7%) 156 (69.3%)  
Median CD4 count (cell/mm3) 616.0 ± 303.9 501.57 ± 309.0 642.70 ± 297.3 0.006
Median viral load (> 40 copy/ml) 19,867.2 ± 72,559.9 16,235.1 ± 4241.9 20,775.2 ± 78,371.9 0.708
ART regimens
 TDF + FTC + RAL 24 (10.7%) 3 (6.7%) 21 (11.7%) 0.375
 TDF + FTC + DTG 17 (7.6%) 5 (11.1%) 12 (6.7%) 0.355
 ABC + 3TC + DTG 28 (12.4%) 10 (22.2%) 18 (10.0%) 0.057
 TDF + FTC + DRV/r 30 (13.3%) 3 (6.7%) 27 (15.0%) 0.188
 TDF + FTC + LPV/r 42 (18.7%) 12 (26.7%) 30 (16.7%) 0.213
 TDF (or TAF) + FTC + EVG/c 84 (37.3%) 12 (26.7%) 72 (40.0%) 0.249
  1. TDF tenofovir disoproxil fumarate, TAF tenofovir alafenamide fumarate, FTC emtricitabine, RAL raltegravir, DTG dolutegravir, ABC abacavir, 3TC lamivudine, DRV/r:darunavir/ritonavir; LPV/r lopinavir/ritonavir; EVG/c elvitegravir/cobicistat
  2. * p < 0.05 was considered significant